Courier Health raises $50M Series B to expand life sciences CRM
Courier Health secured US$50M led by Oak HC/FT to scale its biopharma CRM, focused on patient journey workflows like enrollment and therapy start.
Courier Health has raised US$50 million in a Series B round led by Oak HC/FT, with participation from Norwest Venture Partners and Work-Bench.
The funding will be used to continue product development and scale the company’s commercial footprint as biopharma teams invest in more patient-centric customer relationship management (CRM) and engagement workflows.
Table of contents
Jump to each section:
- What Courier Health is building for biopharma teams
- Why life sciences CRM is shifting toward patient journey operations
- Competitive context: going up against Veeva and enterprise CRMs
- What commercial and patient services leaders should assess
ContentGripWhat Courier Health is building for biopharma teams
Courier Health offers a CRM and patient experience platform designed for biopharma commercial and patient services teams managing multi-step patient journeys, from diagnosis and enrollment through therapy start and adherence.
The company’s product focus is workflow and coordination: connecting data from multiple sources, managing handoffs between internal teams and external stakeholders, and enabling more tailored patient engagement. In this segment, “CRM” is less about classic lead and opportunity tracking and more about orchestrating operational steps that influence time-to-therapy and persistence.
Courier Health has indicated customers have seen outcomes such as a 67% reduction in time-to-start, 7x team efficiency, and an average 15%+ increase in patient starts. Teams evaluating these claims typically need to validate how metrics are defined, what baseline process exists, and whether improvements hold across therapy areas and distributions.
Why life sciences CRM is shifting toward patient journey operations
Life sciences CRM is being pulled toward journey operations because the commercial model increasingly depends on what happens after the prescription decision, not just before it. Friction in onboarding, benefits verification, scheduling, or patient support can reduce starts and adherence, which in turn affects both revenue and patient outcomes.
The macro trend is also toward AI-powered CRM and workflow automation, but in regulated environments automation has to be explainable and compliant. That pushes vendors to invest in structured workflows, permissions, and auditability rather than only generative features.
In practical terms, “patient-centric” CRM often means unifying engagement and operational signals across teams that historically operated in silos, including field, hubs, patient services, case management, and specialty pharmacy coordination.
Competitive context: going up against Veeva and enterprise CRMs
Courier Health is competing in a specialized life sciences CRM category that includes purpose-built platforms and adapted enterprise CRMs. Named competitors in the segment include Veeva Vault CRM, Salesforce Life Sciences Cloud, Microsoft Dynamics 365, and IQVIA.
Differentiation in this market tends to come down to three things:
- Depth in patient services workflows: how well the system supports therapy onboarding and ongoing adherence programs, not just HCP engagement.
- Data connectivity and interoperability: the ability to ingest and normalize data from hubs, pharmacies, payers, and internal systems.
- Time-to-value and operational fit: whether teams can deploy and iterate workflows without multi-quarter customization cycles.
Veeva and large CRMs bring ecosystem maturity and enterprise relationships, but they can require significant configuration to reflect patient journey operations. Courier Health’s opportunity is to offer a more focused operating model for patient engagement workflows, while still meeting enterprise expectations around security, compliance, and reporting.
What commercial and patient services leaders should assess
A US$50 million Series B suggests Courier Health is moving from product build-out to scaled deployment. For buyers, that is a good time to evaluate the platform on execution details:
- Workflow coverage vs edge cases: whether the system handles the messy parts of therapy onboarding (exceptions, escalations, and multi-party coordination).
- Measurement discipline: how the platform attributes improvements like time-to-start reductions, and whether reporting aligns with internal definitions.
- Regulatory and privacy posture: how consent, permissions, and audit trails are handled for patient-facing engagement data.
- Implementation model: what it takes to connect existing data sources and make workflows usable for field, hub, and patient services teams.
Courier Health previously raised a reported US$16.5 million Series A in 2024, and the Series B can be read as continued investor confidence that patient-centric operations will keep reshaping how life sciences organizations define CRM.
